This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tong, W.-G. Articles by Adrian, T. E. Search for Related Content PubMed PubMed Citation Articles by Tong, W.-G. Articles by Adrian, T. E.

Leukotriene B4 Receptor Antagonist LY293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells¹

Department of Surgery, Northwestern University Medical School, Chicago, Illinois 60611 [W-G. T., X-Z. D., R. H., R. C. W., T. E. A.], and The Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198 [J. S., P. M. P.]

Purpose: The effects of leukotriene (LT) B4 and its receptorantagonist LY293111 on proliferation and apoptosis of human pancreatic cancer cells were investigated, both in vitro and in vivo.

Experimental Design: Six human pancreatic cancer cell lines (MiaPaCa-2, HPAC, Capan-1, Capan-2, PANC-1, and AsPC-1) were used. Expression of LTB4 receptors, BLT1 and BLT2, was measured by reverse transcription-PCR. Cell proliferation was measured by [methyl-³H]thymidine incorporation and cell number counting. Extracellular signal-regulated kinase (ERK) 1/2 activation was measured by Western blotting. Apoptosis was assessed by morphology, terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay, and poly(ADP-ribose) polymerase cleavage. The effect of LY293111 on growth of AsPC-1 and HPAC cell xenografts was assessed in BALB/c nu/nu athymic mice.

Results: Both LTB4 receptor types were found to be expressed in human pancreatic cancer cells. The LTB4 receptor antagonist LY293111 caused both time- and concentration-dependent inhibition of proliferation of all six human pancreatic cancer cell lines studied. In contrast, LTB4 stimulated proliferation of these cell lines and induced ERK1/2 phosphorylation. The growth-stimulatory effect and ERK1/2 phosphorylation induced by LTB4 were inhibited by LY293111. Coincident with growth inhibition, LY293111 induced apoptosis in these pancreatic cancer cell lines, as indicated by morphology, TUNEL assay, and poly(ADP-ribose) polymerase cleavage. In studies using AsPC-1 and HPAC cell xenografts in athymic mice, LY293111 treatment markedly inhibited tumor growth over a 24-day treatment period, as measured by both tumor volume and tumor weight. In situ tissue TUNEL assay showed massive apoptosis in LY293111-treated tumor tissues.

Conclusions: LTB4 can directly regulate the growth of human pancreatic cancer cells and control their survival. Additional studies will clarify the underlying mechanisms of LTB4-regulated pancreatic cancer cell growth and apoptosis. LTB4 receptor blockade and inhibition of the downstream signal pathway are likely to be valuable for the treatment of human pancreatic cancer.

This article has been cited by other articles:

				L. G. Melstrom, D. J. Bentrem, M. R. Salabat, T. J. Kennedy, X.-Z. Ding, M. Strouch, S. M. Rao, R. C. Witt, C. A. Ternent, M. S. Talamonti, et al. Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors In vitro and in a Murine Model Clin. Cancer Res., October 15, 2008; 14(20): 6525 - 6530. [Abstract] [Full Text] [PDF]

				D. Nieves and J. J. Moreno Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth J. Lipid Res., December 1, 2006; 47(12): 2681 - 2689. [Abstract] [Full Text] [PDF]

				Z. Sun, S. Sood, N. Li, D. Ramji, P. Yang, R. A. Newman, C. S. Yang, and X. Chen Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors Carcinogenesis, September 1, 2006; 27(9): 1902 - 1908. [Abstract] [Full Text] [PDF]

				G. K. Schwartz, A. Weitzman, E. O'Reilly, L. Brail, D. P. de Alwis, A. Cleverly, B. Barile-Thiem, V. Vinciguerra, and D. R. Budman Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors J. Clin. Oncol., August 10, 2005; 23(23): 5365 - 5373. [Abstract] [Full Text] [PDF]

				R. Hennig, P. Grippo, X.-Z. Ding, S. M. Rao, M. W. Buchler, H. Friess, M. S. Talamonti, R. H. Bell, and T. E. Adrian 5-Lipoxygenase, a Marker for Early Pancreatic Intraepithelial Neoplastic Lesions Cancer Res., July 15, 2005; 65(14): 6011 - 6016. [Abstract] [Full Text] [PDF]

				A. Reversi, V. Rimoldi, T. Marrocco, P. Cassoni, G. Bussolati, M. Parenti, and B. Chini The Oxytocin Receptor Antagonist Atosiban Inhibits Cell Growth via a "Biased Agonist" Mechanism J. Biol. Chem., April 22, 2005; 280(16): 16311 - 16318. [Abstract] [Full Text] [PDF]

				A. Hoque, S. M. Lippman, T.-T. Wu, Y. Xu, Z. D. Liang, S. Swisher, H. Zhang, L. Cao, J. A. Ajani, and X.-c. Xu Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention Carcinogenesis, April 1, 2005; 26(4): 785 - 791. [Abstract] [Full Text] [PDF]

				E. J. Perkins, J. W. Cramer, N. A. Farid, M. G. Gadberry, D. A. Jackson, E. L. Mattiuz, D. D. O'Bannon, H. J. Weiss, W. J. Wheeler, P. G. Wood, et al. PRECLINICAL CHARACTERIZATION OF 2-[3-[3-[(5-ETHYL-4'-FLUORO-2-HYDROXY[1,1'-BIPHENYL]-4-YL)OXY]PROPOXY]-2-PROPYLPHENOXY]BENZOIC ACID METABOLISM: IN VITRO SPECIES COMPARISON AND IN VIVO DISPOSITION IN RATS Drug Metab. Dispos., November 1, 2003; 31(11): 1382 - 1390. [Abstract] [Full Text] [PDF]

				X. Chen, N. Li, S. Wang, N. Wu, J. Hong, X. Jiao, M. J. Krasna, D. G. Beer, and C. S. Yang Leukotriene A4 Hydrolase in Rat and Human Esophageal Adenocarcinomas and Inhibitory Effects of Bestatin J Natl Cancer Inst, July 16, 2003; 95(14): 1053 - 1061. [Abstract] [Full Text] [PDF]